title: Update on hidradenitis suppurativa: connecting the tracts.
abstract: Hidradenitis suppurativa (HS) is a debilitating skin disease characterized by recurrent abscesses, sinus tract formation, and scarring. Prevalence estimates range from 0.053% to 4.1%, although HS is likely an underdiagnosed disease. Although the first reports of HS date back to the mid-19th century, the disease continues to plague patients and physicians desperate for a definitive treatment. Advances in the understanding of the disease process include the possibility of a defective basement membrane at the sebofollicular junction of the folliculopilosebaceous unit (FPSU; that is, where the sebaceous gland empties into the hair follicle) as an initiating event followed by secondary bacterial colonization. New evidence suggests that bacteria living in a community, known as a biofilm, rather than single planktonic bacteria in HS lesions may explain why HS can be resistant to current antibiotic treatment regimens. Available treatment options have expanded to include triple-antibiotic therapy, tumor necrosis factor (TNF-α) and interleukin-1 (IL-1) inhibitors (biologics), laser therapy, and surgical excision, including the skin tissue-sparing excision with electrosurgical peeling procedure. Despite the array of treatments available, many patients continue to struggle with the embarrassment, pain, odor, and frustration that accompany this often isolating disease. Physicians should address comorbidities in HS, including the psychosocial issues patients with HS frequently encounter. Patients can be directed to HS support groups, where they can openly discuss their frustrations, share their experiences in dealing with HS, and band together to advocate for themselves. HS is misunderstood by both patients and physicians, often resulting in a delay in clinical presentation and diagnosis. Patients and physicians across multiple specialties must work together to expand awareness of and interest in HS, so that one day, individuals with HS can be freed from this crippling disease.
authors.affiliation: College of Human Medicine, Michigan State University 965 Fee Road, Room A110, East Lansing, MI 48824 USA.
authors.forename: Liza
authors.initials: L
authors.lastname: Gill
authors.affiliation: Department of Dermatology Henry Ford Hospital, 3031 W. Grand Boulevard, Suite 800, Detroit, MI 48202 USA.
authors.forename: Melissa
authors.initials: M
authors.lastname: Williams
authors.affiliation: Department of Dermatology Henry Ford Hospital, 3031 W. Grand Boulevard, Suite 800, Detroit, MI 48202 USA.
authors.forename: Iltefat
authors.initials: I
authors.lastname: Hamzavi